Merodis advises Vésale Pharma on its sale to Ceres Pharma

Vésale Pharma is a Belgian pioneer in probiotic food supplements, while Ceres Pharma is a dynamic and fast-growing pharmaceutical company active in the development and distribution of drugs, medical devices, biocides, cosmetics, qualitative food supplements and pharmaceutical preparations. This acquisition supports Ceres Pharma’s strategy to strengthen its position as a key player in the European Women & Family Healthcare market.

Vésale Pharma (www.vesalepharma.com) is a pioneering Belgium-based developer and (premixes) manufacturer of branded and non-branded high-quality probiotic food supplements.

Founded in 1996, the Company has built a strong reputation with its focused product portfolio in the Belux region, including Vinalac® and Bacilac Femina®. In Belux, Vésale Pharma promotes its brands to general practitioners, specialists and pharmacists. Beyond those borders, Vésale Pharma partners up with foreign distributors seeking to develop their own probiotic business. These foreign sales are facilitated by Vésale Pharma’s microencapsulation Intelicaps® technology.

Ceres Pharma (www.ceres-pharma.com) is a fast-growing Belgian pharmaceutical company focused on the development and distribution of consumer healthcare products across Europe. Founded in 2017 and backed by Naxicap Partners since 2021, the company is pursuing an ambitious buy-and-build strategy under the direction of founder and CEO Mario Debel. Ceres Pharma offers a diversified portfolio including drugs, medical devices, biocides, cosmetics, qualitative food supplements, and pharmaceutical preparations. Active in Belgium, Italy, and Central and Eastern Europe, the company is steadily expanding its footprint through a combination of organic growth and targeted acquisitions. With a clear focus on Women’s and Family Health, Ceres Pharma is positioning itself as a pan-European player in accessible, science-based healthcare solutions.